Health
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study – BioPharma-Reporter.com
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The novel nasal spray, INNA-051, is being developed by Australian biotech Ena Respiratory. The company has published its animal study, led by Public Health Englands Deputy Director Professor Miles Carroll, on biomedical pre-publication research site medRxiv.
The researchers note that INNA-051 significantly reduced COVID-19 virus levels in the nose and throat. A nasal administration delivered once or twice a week could be used to prevent infection in at-risk populations and healthcare workers, s…
-
General23 hours agoFrom Humpty Doo to the bush, these voters’ views reflect the challenge for federal politicians
-
Noosa News16 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News17 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
Noosa News23 hours agoScenic Rim council cracks down on farmers hosting campers without a permit